Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12345678910111213...15251526»
  • ||||||||||  Review, Journal:  PARP inhibitors in non-ovarian gynecologic cancers. (Pubmed Central) -  Jun 17, 2024   
    We review the development of PARPi strategies for treating patients with endometrial, cervical, uterine leiomyosarcoma, and vulvar cancers. Furthermore, we discuss future directions and the importance of understanding HR deficiency in the context of each cancer type.
  • ||||||||||  Journal:  Multimodal Brain Tumor Classification Using Convolutional Tumnet Architecture. (Pubmed Central) -  Jun 17, 2024   
    The entropy value confirms the presence of additional features in the fused image. The proposed Tumnet yields a sensitivity of 96%, an accuracy of 98%, a specificity of 99%, normalized values of the mean of 0.75, a standard deviation of 0.4, a variance of 0.16, and an entropy of 0.90.
  • ||||||||||  Review, Journal:  Molecular and therapeutic advancements in Capicua (CIC)-rearranged sarcoma. (Pubmed Central) -  Jun 17, 2024   
    Moreover, the recent development of preclinical models to study CIC::DUX4 sarcoma have advanced our understanding of the underlying biological mechanisms and uncovered key dependencies that can be translated into rational therapies. In this review, we will highlight these recent advancements in CIC-rearranged sarcoma biology with a vision for clinical translation to improve patient outcomes.
  • ||||||||||  Journal:  Molecular mechanism of RBM14-mediated promotion of proliferation, migration, and invasion in osteosarcoma. (Pubmed Central) -  Jun 17, 2024   
    The above-mentioned findings underscore the significant importance of RBM14 as an intriguing target for therapy for the mitigation and management of OS. This particular protein holds an excellent opportunity for the development of novel and efficacious therapeutic approaches that possess the potential to yield favorable results for patients affected with OS.
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Journal:  Spontaneous remission of a pulmonary sclerosing epithelioid fibrosarcoma: a case report of a possible abscopal effect. (Pubmed Central) -  Jun 17, 2024   
    After progression to pazopanib and other ChT drugs, because of the chest pain associated with a pleural mass invading the second costal arch, the patient received antalgic local RT treatment...As far as reported in the literature, this is the first case of SR in SEF. Among the possible causes of this SR, we think that the most plausible is that palliative treatment with RT of the pleural mass induced an AE, leading to a reduction of all tumoral lesions, even those outside the irradiated region.
  • ||||||||||  Journal:  A rare case report of endometrial adenosarcoma in the cesarean scar diverticulum. (Pubmed Central) -  Jun 17, 2024   
    Hysteroscopy can serve as a valuable diagnostic tool to identify the lesion in this unique scenario, particularly when curettage fails to diagnose this uncommon condition. We hope that this case would bring awareness of this potential scenario, enabling clinicians in the future to identify similar cases more readily.
  • ||||||||||  Journal:  Exceptional case of a hemangioma-like rabdomyosarcoma in the hand's palm. (Pubmed Central) -  Jun 17, 2024   
    In similar cases recorded in the literature, the diagnosis may be first mistaken for that of a hemangioma, then confirmed by histology. This underlines the importance of a systematic anatomopathological examination of all tissues removed surgically.
  • ||||||||||  erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
    Journal:  Application of copper (I) selective ligands for PET imaging of reactive oxygen species through metabolic trapping. (Pubmed Central) -  Jun 16, 2024   
    PET imaging of ROS would be possible by using a copper (I) selective ligand, based on metabolic trapping. Although improvement of the membrane permeability and the stability of copper (I) complexes is required, the present results pave the way for the development of novel 64Cu-labeled complexes for PET imaging of ROS.
  • ||||||||||  Journal, IO biomarker:  Fate control engagement augments NK cell responses in LV/hu-IL-12 transduced sarcoma. (Pubmed Central) -  Jun 16, 2024   
    mTMPK fate control engagement terminates transduced sarcoma IL-12 production and triggers cell death, but also augments an NK cell-mediated response coinciding with metabolic stress activating surface ligand induction. Fate control engagement could offer a novel immune activation method for NK cell-mediated cancer clearance.
  • ||||||||||  Journal:  From biology to personalized medicine: recent knowledge in Osteosarcoma. (Pubmed Central) -  Jun 16, 2024   
    The development of new technologies like next generation sequencing has led to an improvement in osteosarcoma oncogenesis. This review summarizes recent biological and therapeutical advances in osteosarcoma, as well as the challenges that must be overcome in order to develop personalized medicine and new therapeutic strategies and ultimately improve patient survival.
  • ||||||||||  Discussion led by Chair (Oviedo Auditorium - Hall 3) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_858;    
  • ||||||||||  Presentation by Expert (Oviedo Auditorium - Hall 3) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_857;    
  • ||||||||||  Discussion (Santander Auditorium - Hall 5) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_554;    
  • ||||||||||  Q&A and discussion (Alicante Auditorium - Hall 3) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_302;    
  • ||||||||||  Q&A and discussion (Santander Auditorium - Hall 5) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_258;    
  • ||||||||||  Landmark trials in GIST (Santander Auditorium - Hall 5) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_257;    
  • ||||||||||  Hot topics in sarcoma (Santander Auditorium - Hall 5) -  Jun 16, 2024 - Abstract #ESMO2024ESMO_252;